Article
Rheumatology
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
Summary: This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyze other risk factors for diabetes. The results showed that certain DMARDs can reduce the risk of diabetes.
Review
Rheumatology
Maike H. M. Wientjes, Alfons A. den Broeder, Paco M. J. Welsing, Lise M. Verhoef, Bart J. F. van den Bemt
Summary: This systematic review aimed to identify laboratory biomarkers that predict response to tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). The review found that no biomarkers consistently showed a strong predictive effect for response to TNFi in RA patients. Future research should focus on exploring, combining, and validating the most promising laboratory biomarkers identified in this review, as well as searching for new predictors.
Article
Rheumatology
Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L. Hyrich, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Darren Plant, Anne Barton
Summary: The study aimed to explore whether the inflammatory protein MRP8/14 can serve as a biomarker for treatment response in rheumatoid arthritis (RA) patients receiving tumor necrosis factor (TNF) inhibitors. The results showed that in the 3-component and 2-component models, patients with high pre-treatment levels of MRP8/14 were 1.92 and 2.03 times more likely to be classified as EULAR responders compared to those with low levels. However, no significant associations were observed in the 4-component model. Conclusion: Apart from its correlation with CRP, there is no evidence to suggest that MRP8/14 explains additional variability in response to TNFi in RA patients beyond CRP alone.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Johan Law-Wan, Marc-Antoine Sparfel, Sophie Derolez, Nicolas Azzopardi, Philippe Goupille, Jacqueline Detert, Denis Mulleman, Theodora Bejan-Angoulvant
Summary: In rheumatoid arthritis (RA), patients who are more responsive to TNFi are those who are non-obese, have a longer disease duration, and have a higher initial disease activity. Results from analyzing individual data of 11,617 patients from 29 RCTs highlight the importance of these patient characteristics in predicting responsiveness to TNFi therapy.
Article
Rheumatology
Helga Westerlind, Bente Glintborg, Hilde Berner Hammer, Saedis Saevarsdottir, Niels Steen Krogh, Merete Lund Hetland, Ellen-Margrethe Hauge, Isabel Martinez Tejada, Joseph Sexton, Johan Askling
Summary: This study aims to describe how data harmonization can be achieved in rheumatoid arthritis (RA) and found that the proportion of patients reaching remission in RA treatment is low.
Article
Immunology
Ana Carolina Matias Dinelly Pinto, Rodolfo de Melo Nunes, Igor Albuquerque Nogueira, Bernhard Fischer, Rudolf Lucas, Virginia Claudia Carneiro Girao-Carmona, Vivian Louise Soares de Oliveira, Flavio Almeida Amaral, Georg Schett, Francisco Airton Castro Rocha
Summary: TNF inhibitors are commonly used for the treatment of arthropathies like rheumatoid arthritis (RA), but not all patients achieve remission and there is a risk of infection. This study found that the lectin-like domain of TNF has anti-inflammatory effects and can mitigate the development of immune-mediated arthritis in mice.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Woorim Kim, Soo Jin Oh, Nga Thi Trinh, Jin Yeon Gil, In Ah Choi, Ji Hyoun Kim, Joo Hee Kim, Ju-Yang Jung, Jinhyun Kim, Hyoun-Ah Kim, Kyung Eun Lee
Summary: This study aimed to investigate the effects of genetic polymorphisms in RETN on the remission of RA patients receiving TNF-alpha inhibitors, and use machine learning algorithms to predict remission. The results showed that the most significant features associated with the efficacy of TNF-alpha inhibitors included sex, age, hypertension, sulfasalazine, and several genetic polymorphisms. The elastic net algorithm was found to be the best method for predicting remission in RA patients treated with TNF-alpha inhibitors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Rheumatology
Daniel H. Solomon, Jon T. Giles, Katherine P. Liao, Paul M. Ridker, Pamela M. Rist, Robert J. Glynn, Rachel Broderick, Fengxin Lu, Meredith T. Murray, Kathleen Vanni, Leah M. Santacroce, Shady Abohashem, Philip M. Robson, Zahi Fayad, Venkatesh Mani, Ahmed Tawakol, Joan Bathon
Summary: This study found that adding either a TNFi or triple therapy led to clinically important improvements in vascular inflammation. However, adding a TNFi did not reduce arterial inflammation more than triple therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Alejandro Ibanez-Costa, Carlos Perez-Sanchez, Alejandra Maria Patino-Trives, Maria Luque-Tevar, Pilar Font, Ivan Arias de la Rosa, Cristobal Roman-Rodriguez, Ma Carmen Abalos-Aguilera, Carmen Conde, Antonio Gonzalez, Sergio Pedraza-Arevalo, Mercedes del Rio-Moreno, Ricardo Blazquez-Encinas, Pedro Segui, Jerusalem Calvo, Rafaela Ortega Castro, Alejandro Escudero-Contreras, Nuria Barbarroja, Ma Angeles Aguirre, Justo P. Castano-Fuentes, Raul M. Luque, Eduardo Collantes-Estevez, Chary Lopez-Pedrera
Summary: This study identified altered expression of several splicing machinery elements in leucocytes of rheumatoid arthritis patients, with 8 elements equally affected in all leucocyte subtypes. These alterations could discriminate patients from healthy donors, classify high disease activity, recognize radiological involvement, and identify patients with atheroma plaques. The signature was also found in RA synovial fluid and ankle joints of arthritic mice, and could be reversed by anti-TNF therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Vincent Bouget, Julien Duquesne, Signe Hassler, Paul-Henry Cournede, Bruno Fautrel, Francis Guillemin, Marc Pallardy, Philippe Broet, Xavier Mariette, Samuel Bitoun
Summary: Machine learning models were developed to predict patient response to TNFi using simple clinical and biological data, and achieved promising results in both training and replication cohorts.
Article
Rheumatology
Imane Bardan, Karen M. Fagerli, Joe Sexton, Tore K. Kvien, Gunnstein Bakland, Pawel Mielnik, Yi Hu, Gunhild Lien, Berit Flato, Oyvind Molberg, Eirik K. Kristianslund, Anna-Birgitte Aga
Summary: This study compared the effectiveness of tumor necrosis factor inhibitors (TNFi) and comedication, as well as methotrexate (MTX) monotherapy, in patients with adult juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). The results showed that JIA patients had lower baseline disease activity compared to RA patients in different treatment groups. After baseline disease activity adjustment, there were no significant differences in disease activity change between JIA and RA patients for both treatment groups. TNFi and MTX monotherapy are both effective in adult JIA, with similar effectiveness to that shown in RA.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Daniel J. Lightwood, Rebecca J. Munro, John Porter, David McMillan, Bruce Carrington, Alison Turner, Anthony Scott-Tucker, Elizabeth S. Hickford, Antje Schmidt, David Fox, Alison Maloney, Tom Ceska, Tim Bourne, James O'Connell, Alastair D. G. Lawson
Summary: TNF can be inhibited by small molecules that stabilize the TNF trimer in an asymmetric conformation. The authors also developed a monoclonal antibody that selectively binds this inactive form of TNF, enabling both target engagement assessment and structural characterization of TNF binding to TNF receptor 1.
NATURE COMMUNICATIONS
(2021)
Article
Rheumatology
Hieronymus T. W. Smeele, Esther Roder, Annemarie G. M. G. J. Mulders, Eric A. P. Steegers, Radboud J. E. M. Dolhain
Summary: This study is the first to show that the use of TNFi during pregnancy is associated with increased birth weight in offspring of women with well-controlled RA. Further research is needed to explore the underlying mechanism of TNF inhibition on birth weight and its long-term consequences for the offspring.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Siri Lillegraven, Nina Paulshus Sundlisaeter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Ase Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Hoili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Desiree Van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Summary: This study aimed to assess the effect of tapering tumor necrosis factor inhibitor (TNFi) to withdrawal compared with stable treatment on the risk of disease activity flares in patients with rheumatoid arthritis (RA) in remission for more than 1 year. The results showed that in the tapering TNFi group, 63% experienced a flare during 12 months, compared to 5% in the stable TNFi group. Therefore, tapering TNFi to discontinuation is not non-inferior to continued stable treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Johanna Elin Gehin, Silje Watterdal Syversen, David John Warren, Guro Lovik Goll, Joseph Sexton, Nils Bolstad, Hilde Berner Hammer
Summary: The study aimed to identify the therapeutic range for etanercept and assess the incidence of anti-etanercept antibody formation. Despite associations found between etanercept concentration and disease activity, no therapeutic range could be identified, and no patients developed anti-etanercept antibodies during the study.
Article
Rheumatology
T. Thomsen, B. A. Esbensen, M. L. Hetland, M. Aadahl
Summary: A randomized controlled trial aimed to reduce sedentary behaviour and increase light-intensity physical activity in patients with rheumatoid arthritis. The study found that patients who are less educated and have certain types of comorbidity are less motivated to participate in physical activity interventions. The findings can help improve recruitment processes and implementation of physical activity interventions in rheumatology clinical practice.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
M. A. Nielsen, D. Koster, S. Greisen, A. Troldborg, K. Stengaard-Pedersen, P. Junker, K. Horslev-Petersen, M. L. Hetland, M. Ostergaard, M. Hvid, H. Leffler, T. W. Kragstrup, B. Deleuran
Summary: The study found that patients with rheumatoid arthritis (RA) had persistently increased levels of galectin-3 (Gal-3) in their plasma, and changes in Gal-3 levels were associated with long-term disease activity. Gal-3 levels in synovial fluid were also significantly elevated. In vitro experiments showed that a Gal-3 inhibitor could reduce the activity of inflammatory cells.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen
Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Bente Glintborg, Daniela Di Giuseppe, Johan K. Wallman, Sella A. Provan, Dan Nordstrom, Anna-Mari Hokkanen, Jenny Osterlund, Eirik Kristianslund, Tore K. Kvien, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen, Lennart Jacobsson, Johan Askling, Ulf Lindstrom
Summary: This study aims to assess the safety of secukinumab and TNF inhibitors in the treatment of SpA and PsA. The study found that the risk of hospitalized infection during the first year of treatment with secukinumab was higher compared to adalimumab, potentially due to confounding factors.
Article
Rheumatology
Kristine M. Latocha, Katrine B. Loppenthin, Mikkel Ostergaard, Poul J. Jennum, Merete L. Hetland, Henrik Rogind, Tine Lundbak, Julie Midtgaard, Robin Christensen, Bente A. Esbensen
Summary: The objective of the study was to compare the effects of cognitive behavioural therapy for insomnia (CBT-I) to usual care on sleep efficiency. The study found that CBT-I did not significantly improve sleep efficiency measured by polysomnography (PSG). However, CBT-I showed significant improvement in patient-reported sleep and RA-related outcomes.
Article
Rheumatology
M. B. Raft, M. L. Hetland, C. H. Brahe, K. Horslev-Petersen, L. Midtboll Ornbjerg, P. Junker, N. Biln, K. Stengaard-Pedersen, M. Ostergaard
Summary: This study evaluated the predictive role of serum 14-3-3 eta for disease activity and radiographic progression in early RA patients. The results showed that 14-3-3 eta can predict the risk of radiographic progression, especially in ACPA-negative patients.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
E. B. Rasmussen, L. S. Thiele, K. Stengaard-Pedersen, M. L. Hetland, K. Horslev-Petersen, P. Junker, M. Ostergaard, A. S. Hansen, M. Hvid, B. Deleuran, S. R. Greisen
Summary: ACPAs IgA and IgG have weak associations with disease activity in early RA, but are not superior in predicting long-term radiographic progression.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Correction
Rheumatology
Lykke M. Ornbjerg, Louise Linde, Stylianos Georgiadis, Simon H. Rasmussen, Ulf Lindstrom, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K. Wallman, Karel Pavelka, Jakub Zavada, Michael J. Nissen, Gareth T. Jones, Heikki Relas, Laura Pirila, Matija Tomsic, Ziga Rotar, Arni Jon Geirsson, Bjorn Gudbjornsson, Eirik K. Kristianslund, Irene van der Horst-Bruinsma, Anne Gitte Loft, Karin Laas, Florenzo Iannone, Addolorata Corrado, Adrian Ciurea, Maria J. Santos, Helena Santos, Catalin Codreanu, Nurullah Akkoc, Ozgul S. Gunduz, Bente Glintborg, Mikkel Ostergaard, Merete Lund Hetland
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Cell Biology
Morten A. A. Nielsen, Ditte Koster, Akul Y. Y. Mehta, Kristian Stengaard-Pedersen, Pierre Busson, Peter Junker, Kim Horslev-Petersen, Merete Lund Hetland, Mikkel ostergaard, Malene Hvid, Hakon Leffler, Tue W. W. Kragstrup, Richard D. D. Cummings, Bent Deleuran
Summary: This study evaluated the clinical and pathogenic aspects of Gal-9 in rheumatoid arthritis (RA) and found that it plays a role in modulating synovial FLS activities and maintaining subclinical disease activity.
Article
Rheumatology
Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C. Nordstrom, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A. Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindstrom
Summary: This study aimed to describe the uptake and effectiveness of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the Nordic countries. The results showed that the uptake of newer b/tsDMARDs increased from 2014 and plateaued in 2018. Regardless of treatment course, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved low disease activity (LDA).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Public, Environmental & Occupational Health
Kristina Laugesen, Jonas Mengel-From, Kaare Christensen, Jorn Olsen, David M. Hougaard, Lasse Boding, Anja Olsen, Christian Erikstrup, Merete Lund Hetland, Estrid Hogdall, Alisa Kjaergaard, Erik Sorensen, Anja Brugmann, Eva Rabing Brix Petersen, Ivan Brandslund, Borge Nordestgaard, Gorm B. Jensen, Nils Skajaa, Frederikke Schonfeldt Troelsen, Cecilia Hvitfeldt Fuglsang, Lise Skovgaard Svingel, Henrik T. Sorensen
Summary: Denmark has a rich source of biobanks and a comprehensive healthcare system, which allows for the integration of biological specimens with clinical and demographic data for biobank research. This can contribute to a better understanding of disease etiology and personalized medicine.
CLINICAL EPIDEMIOLOGY
(2023)
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Helga Westerlind, Bente Glintborg, Hilde Berner Hammer, Saedis Saevarsdottir, Niels Steen Krogh, Merete Lund Hetland, Ellen-Margrethe Hauge, Isabel Martinez Tejada, Joseph Sexton, Johan Askling
Summary: This study aims to describe how data harmonization can be achieved in rheumatoid arthritis (RA) and found that the proportion of patients reaching remission in RA treatment is low.
Article
Rheumatology
Janni Maria Pedersen, Aida Solhoj Hansen, Caecilie Skejo, Kristian Juul-Madsen, Peter Junker, Kim Horslev-Petersen, Merete Lund Hetland, Kristian Stengaard-Pedersen, Mikkel ostergaard, Bjarne Kuno Moller, Lene Dreyer, Ellen-Margrethe Hauge, Malene Hvid, Stinne Greisen, Bent Deleuran
Summary: This study investigated the role of lymphocyte activation gene-3 (LAG-3) as a serological marker and mediator in the pathogenesis of rheumatoid arthritis (RA). The results showed increased levels of LAG-3 in both early and chronic RA patients, particularly in the inflamed joint. LAG-3 plays a biological role in reducing inflammatory cytokine production in chronic RA, and this function is not affected by Gal-3 interference. Our findings suggest that LAG-3 is a multifaceted regulator of inflammation in early and chronic RA.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Tanja Thomsen, Mette Aadahl, Merete Lund Hetland, Bente Appel Esbensen
Summary: A higher proportion of rheumatoid arthritis patients are physically inactive. Lack of consistent physical activity guidance from health professionals may be a barrier. This study explores patients' perspectives on current and future guidance and emphasizes the importance of integrated physical activity focus in rheumatology clinics, with adequate training for health professionals.
RHEUMATOLOGY INTERNATIONAL
(2023)